US Patent Issued to Duke University on March 17 for "LRRK2 mutations as biomarkers for the prediction of immune checkpoint response in cancer" (North Carolina Inventors)

ALEXANDRIA, Va., March 17 -- United States Patent no. 12,577,621, issued on March 17, was assigned to Duke University (Durham, N.C.).

"LRRK2 mutations as biomarkers for the prediction of immune checkpoint response in cancer" was invented by Laurie Andolina (Durham, N.C.) and Edgardo Parrilla Castellar (Durham, N.C.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure describes methods and compositions involving using LRRK2 mutations as biomarkers for the prediction of immune checkpoint response in cancer and methods and compositions for treating cancers having certain LRRK2 mutations in a subject."

The patent was filed on Sept. 8, 2021, under Application No. 17/469,507.

*For further inform...